Alain Munoz - Auris Medical Director
Director
Dr. Alain Munoz, M.D. Ph.D., is Director of the Company. He is an entrepreneur and consultant in the healthcare industry. He started his professional career as a cardiologist and anesthesiologist at the university hospital of Montpellier, France. In 1983 he switched to the pharmaceutical industry to become head of the cardiovascular department at Sanofi Research. Two years later, he was appointed Project Leader Cardiovascular and AntiThrombotic Products, followed in 1987 by his promotion to Vice President International Development. In 1990, Dr. Munoz moved to privately held Groupe Fournier to become Vice President of Research Development. In 1997, he was appointed Senior Vice President of the Pharmaceutical Division. In 2000, he left Fournier to launch his own companies, Amistad Pharma for proprietary drug development, and Science Business Development for consulting services. Under Dr. Munoz leadership, numerous worldwide drugs were developed and approved for marketing . He served for several years on the scientific committee of the French Drug Agency, and is Member of the Board of Directors of several biotechnology companies. In addition, Dr. Munoz is an adviser to institutional investors as such, he represents AGF Private Equity on the Company Board of Directors. since 2018.
| Age | 68 |
| Tenure | 6 years |
| Professional Marks | Ph.D |
| Phone | 441 295 5950 |
| Web | http://www.aurismedical.com |
Auris Medical Management Efficiency
The company has return on total asset (ROA) of (21.99) % which means that it has lost $21.99 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (71.91) %, meaning that it created substantial loss on money invested by shareholders. Auris Medical's management efficiency ratios could be used to measure how well Auris Medical manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 523.92 K in liabilities with Debt to Equity (D/E) ratio of 0.03, which may suggest the company is not taking enough advantage from borrowing. Auris Medical Holding has a current ratio of 3.75, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Auris Medical until it has trouble settling it off, either with new capital or with free cash flow. So, Auris Medical's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Auris Medical Holding sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Auris to invest in growth at high rates of return. When we think about Auris Medical's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| James Henderson | BK Technologies | 59 | |
| Robert Purgason | LB Foster | 62 | |
| Joycelyn CarterMiller | NETGEAR | 56 | |
| Michael Dill | BK Technologies | 52 | |
| Thomas McKane | LB Foster | 70 | |
| Lothar Maier | FormFactor | 63 | |
| Jocelyn CarterMiller | NETGEAR | 59 | |
| William Rackoff | LB Foster | 69 | |
| Suzanne Rowland | LB Foster | 56 | |
| James Kennedy | United Airlines Holdings | 64 | |
| John Hanson | Arrow Electronics | 74 | |
| Ryan Turner | BK Technologies | 39 | |
| Bradley Maiorino | NETGEAR | 47 | |
| David Vitale | United Airlines Holdings | 71 | |
| Jane Garvey | United Airlines Holdings | 74 | |
| Laurel Krzeminski | Arrow Electronics | 66 | |
| John Struble | BK Technologies | 41 | |
| Dirk Junge | LB Foster | 69 | |
| Fabian Garcia | Arrow Electronics | 61 | |
| James Whitehurst | United Airlines Holdings | 50 | |
| Michael Zellner | FormFactor | 62 | |
Management Performance
| Return On Equity | -71.91 | |||
| Return On Asset | -21.99 |
Auris Medical Holding Leadership Team
Elected by the shareholders, the Auris Medical's board of directors comprises two types of representatives: Auris Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Auris. The board's role is to monitor Auris Medical's management team and ensure that shareholders' interests are well served. Auris Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Auris Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Cindy McGee, Head of Investor Relations and Corporate Communications | ||
| Hernan Levett, CFO | ||
| James Healy, Non-Executive Independent Vice Chairman of the Board | ||
| Bettina Stubinski, Chief Medical Officer | ||
| Thomas Meyer, Founder, Chairman, CEO and Managing Director | ||
| Calvin Roberts, Non-Executive Independent Director | ||
| Wolfgang Arnold, Board Member | ||
| Oliver Kubli, Board Member | ||
| Thomas Jung, Chief Development Officer | ||
| Andrea Braun, Head of Regulatory and Quality Affairs | ||
| Mats Blom, Director | ||
| Antoine Papiernik, Non-Executive Independent Director | ||
| Anne Zoller, General Counsel | ||
| Berndt Modig, Non-Executive Independent Director | ||
| Sven Zimmermann, CFO | ||
| Armando Anido, Non-Executive Independent Director | ||
| Alain Munoz, Director |
Auris Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Auris Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -71.91 | |||
| Return On Asset | -21.99 | |||
| Current Valuation | 32.76 M | |||
| Shares Outstanding | 12.87 M | |||
| Shares Owned By Insiders | 5.45 % | |||
| Shares Owned By Institutions | 5.34 % | |||
| Number Of Shares Shorted | 362.97 K | |||
| Price To Earning | (1.05) X | |||
| Price To Book | 2.07 X | |||
| Price To Sales | 224.60 X |
Pair Trading with Auris Medical
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Auris Medical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Auris Medical will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Sealed Air could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sealed Air when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sealed Air - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sealed Air to buy it.
The correlation of Sealed Air is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sealed Air moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sealed Air moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Sealed Air can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Other Consideration for investing in Auris Stock
If you are still planning to invest in Auris Medical Holding check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Auris Medical's history and understand the potential risks before investing.
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |